Pennsylvania Perio & Implants today announced the reinforcement of its evidence-based framework for periodontal evaluation and dental implant assessment across its York and Hanover locations. Under ...
The JS001sc-002-III-NSCLC Study is a multi-center, open-label, randomized Phase 3 clinical study led by the principal investigator Professor Lin WU from Hunan Cancer Hospital. JS001sc-002-III-NSCLC is ...
For the quarter ending December 31, 2025, management expects gross revenue of more than US$30.0 million from sales of Ryoncil ® (remestemcel-L-rknd). This represents more than 37% increase on the ...
The world-renowned, peer-reviewed, open-access Nature journal, Signal Transduction and Targeted Therapy, publishes original research on cutting-edge experimental and clinical advances on ...
The webcast of the fireside chat discussion will be available through the investor section of the company’s website at www.oricpharma.com. A replay of the webcast will be available for 90 days ...
8th Annual Evercore Healthcare Conference Date: Wednesday, December 3, 2025 at 8:45 am E.T. Location: Coral Gables, FL Presenter: Chief Executive Officer, Talat Imran, and Chief Financial Officer, ...
HYRNUO is a reversible kinase inhibitor of human epidermal growth factor receptor 2 (HER2). In vitro, HYRNUO inhibited the phosphorylation of HER2, downstream signaling in cancer cells with HER2 ...
The live webcast of the fireside chat will be available on the “Investors & Media” page under the “Events & Presentations” section of the Company’s website at https://ir.aurabiosciences.com/events-and ...
IRVINE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in a fireside chat at the BTIG 5 th Annual Ophthalmology ...
The Company has received notification that Piper Sandler, acting as stabilization agent, has carried out stabilization activities (as defined in Article 3.2 (d) of Regulation (EU) No 596/2014 of the ...
The AES meeting is a cornerstone for the epilepsy community, bringing together science, clinical innovation, and patient advocacy,” said Steven Petrou, chief scientific officer and co-founder of ...
One-time dose of Itvisma replaces SMN1 gene, potentially reducing the need for chronic SMA treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback